The micronutrient element selenium (Se) has been shown to be effective in reducing the incidence of cancer in animal models and human clinical trials. Selenoproteins and low molecular weight Se compounds were implicated in the chemopreventive effect, but specific mechanisms are not clear. We examined the role of Se and selenoproteins in liver tumor formation in TGFa/c-Myc transgenic mice, which are characterized by disrupted redox homeostasis and develop liver cancer by 6 months of age. In these mice, both Se deficiency and high levels of Se compounds suppressed hepatocarcinogenesis. In addition, both treatments induced expression of detoxification genes, increased apoptosis and inhibited cell proliferation. Within low-to-optimal levels of dietary Se, tumor formation correlated with expression of most selenoproteins. These data suggest that changes in selenoprotein expression may either suppress or promote tumorigenesis depending on cell type and genotype. Since dietary Se may have opposing effects on cancer, it is important to identify the subjects who will benefit from Se supplementation as well as those who will not.
Introduction
The micronutrient element selenium (Se) has been shown to be effective in reducing the incidence of cancer in animal models and human clinical trials (Clark et al., 1996; Yu et al., 1997; Yoshizawa et al., 1998; Milner et al., 2001; Ip et al., 2002) . Of the more than 100 reported studies that have examined the chemopreventive potential of Se, approximately two-thirds demonstrated a protective effect and the remaining studies reported no effect. A double-blind clinical trial showed that supplementing a diet with Se resulted in a significant decrease in cancer mortality and overall cancer incidence (Clark et al., 1996) . In this study of 1312 individuals, supplementation of the normal diet with 200 mg of Se daily resulted in decreases of 63, 58, and 48% in the incidence of prostate, colon, and lung cancers, respectively (Clark et al., 1996) . However, in the same study, a chemopreventive effect of this micronutrient on the incidence of melanoma was not observed.
The biochemical basis for the protective effect of Se against cancer is not well understood. A number of mechanisms have been proposed, which are based on two major ideas. One considers that the chemopreventive action of dietary Se is mediated by an increased abundance in Se-containing proteins, while the other that low molecular weight Se-containing compounds (or selenocompounds) are responsible for the chemopreventive effect (Ganther, 1999; Whanger, 2004) . The term of low molecular weight selenocompounds refers herein to Se-containing organic and inorganic compounds that have potent cancer prevention potential. Among the best characterized Se compounds that decrease cancer incidence in various rodent models or inhibit growth of human cancer cells are methylselenenic acid, methylselenocysteine, and selenomethionine. Whether selenoproteins may provide the protection against cancers at an optimal nutritional concentration of Se, and low molecular weight Se compounds at higher concentration, is not known.
The predominant biological form of Se in mammals at low, suboptimal, and optimal dietary levels of this element is selenocysteine in proteins (Sunde, 1994) . Under these conditions, selenoproteins contain >90% of the Se pool in mammals. Selenocysteine is encoded by the UGA codon and is recognized as the 21st amino acid in protein (Low and Berry, 1996; Stadtman, 1996; Bock, 2000; Hatfield, 2001; Driscoll and Copeland, 2003) . There are 25 human and 24 mouse selenoproteins (Kryukov et al., 2003) .
In the present report, we used a well-characterized transgenic mouse model of liver cancer, in which hepatocyte-specific coexpression of c-Myc oncogene and transforming growth factor alpha (TGFa) leads to rapid hepatocellular carcinoma (HCC) development with high penetrance (Santoni-Rugiu et al., 1996) . The trademark features of liver oncogenesis in TGFa/c-Myc mice are chronic oxidative stress resulting from increased production of reactive oxygen species and genomic instability (Factor et al., , 2000 Hironaka et al., 2003; Calvisi et al., 2004) . In contrast to expectations, we found that not only supplementation of the diet with high levels of Se but also Se deficiency suppressed tumorigenesis in this model. Our study implicated selenoproteins in tumor formation in TGFa/c-Myc mice and suggested that some cancers may be promoted by dietary Se supplementation.
Results

Regulation of selenoprotein expression in TGFa/c-Myc mice
By performing metabolic labeling of mice with 75 Se, we analysed the distribution of selenoproteins by SDS-PAGE in TGFa/c-Myc mice at the early dysplastic stage (10 weeks) and tumor stage (27 weeks) (Supplementary Figure S1 ). There were no significant differences in the labeling pattern between dysplastic livers at 2 and 6 months of age. However, in the tumors derived from 6-month-old mice, expression of glutathione peroxidase 1 (GPx1; a major 25 kDa 75 Se-labeled band) was significantly reduced, whereas expression of thioredoxin reductase 1 (TR1; a 55 kDa 75 Se-labeled band) appeared to be slightly elevated (Supplementary Figure S1) . These data were consistent with the possibility that tumorigenesis alters selenoprotein expression in these mice. Thus, it is also possible that changes in selenoprotein levels might influence the incidence of cancer in TGFa/c-Myc mice.
Se diets
Regulation of selenoprotein expression in TGFa/c-Myc mice was further analysed by changing dietary levels of Se. Torula yeast Se-deficient diet (designated as the 0 ppm Se diet) was used. We also supplied this diet with 0.1, 0.4, and 2.25 ppm Se (0.1, 0.4, and 2.25 ppm Se diets, respectively) (see Materials and methods for the rationale regarding the use of diets). A fifth diet was the 0 ppm Se diet supplemented with 30 ppm triphenylselenonium (TPS) chloride (designated the TPS diet). This diet served as a control diet that achieved selenoprotein deficiency in the presence of high levels of Se in the diet.
Regulation of selenoprotein expression by dietary Se
Expression and/or catalytic activity of several selenoproteins were assessed in livers of TGFa/c-Myc mice fed the five Se diets. Glutathione peroxidase activity was reduced approximately 25-and 50-fold in mice on the 0 ppm Se diet relative to 0.1 and 0.4 ppm Se diets, respectively ( Figure 1a ). The increase in Se above 0.4 ppm (the 2.25 ppm Se diet) did not result in an additional increase in GPx activity. GPx activity in transgenic mice maintained on the TPS diet was similar to that observed in mice fed the 0 ppm Se diet. Although this enzyme activity assay measured total glutathione peroxidase activity, GPx1 is by far the most active (and abundant) glutathione peroxidase. Therefore, this assay primarily measured GPx1 activity.
The activity of selenoprotein R (SelR), which is a major methionine-R-sulfoxide reductase in mammals, was regulated by Se similarly to the GPx activity (Figure 1b) , with a dramatic decrease in 0 ppm Se and TPS diets and maximal activity in 0.4 and 2.25 ppm diets. Expression of GPx1 and SelR were also assessed by immunoblot assays. Both proteins were undetectable in mice fed 0 ppm Se and TPS diets and were significantly reduced in the 0.1 ppm Se dietary group (relative to the 0.4 ppm Se group) (Figure 1d ). Two additional selenoproteins, 15 kDa selenoprotein (Sep15) and TR1 were less responsive to changes in Se levels in the diets (Figure 1d , e, respectively). There was little difference in their expression between 0.1, 0.4, and 2.25 ppm Se diets. However, Se deficiency (0 ppm Se) as well the TPS diet resulted in a significant reduction in their expression levels (although less dramatic than that of GPx1 and SelR). A fifth protein analysed, mitochondrial thioredoxin reductase 3 (TR3), did not respond significantly to Se availability (Figure 1e ).
Since selenoprotein deficiency was expected to cause oxidative stress, we reasoned that certain compensatory antioxidant pathways could be upregulated in the 0 ppm Se group. We assayed catalase activity and found that 0 ppm Se and TPS diets resulted in increased catalase activity (Figure 1c) . However, there were no obvious differences in levels of oxidized glutathione or in the ratio of oxidized to reduced glutathione in mice maintained on the five diets (data not shown).
Regulation of the liver/body mass ratio by Se
We observed no significant differences in body weights between different groups of TGFa/c-Myc mice, although mice fed 0.4 and 2.25 ppm Se diets were about 7-10% larger (39.470.2 and 38.770.6 g, respectively). The effect of dietary Se supplementation on liver mass was more pronounced. Mice, which received 0.1 ppm Se, displayed a transgene-induced hepatomegaly characteristic of fast-growing TGFa/c-Myc livers. However, the liver/body weight ratios progressively decreased with increase in dietary Se (6.6970.26%, P ¼ 0.013 and 5.9570.26%, P ¼ 0.06 in mice fed 0.4 and 2.25 ppm Se diets, respectively, as compared to 8.1870.58% in the 0.1 ppm Se group). Similar decrease in liver mass was found in mice maintained on the TPS diet (6.0770.59%, P ¼ 0.037 as compared to the 0.1 ppm Se group), whereas Se deficiency (0 ppm Se) did not significantly affect liver mass (P ¼ 0.247).
Regulation of hepatic tumor formation in TGFa/c-Myc mice by Se
TGFa/c-Myc mice develop hepatic tumors by 6-8 months of age. To determine whether and how changes in selenoprotein expression and concentration of Se compounds affected TGFa/c-Myc-mediated hepatocarcinogenesis, we maintained mice on the 0 ppm Se (n ¼ 11), 0.1 ppm Se (n ¼ 10), 0.4 ppm Se (n ¼ 12), 2.25 ppm Se (n ¼ 8), and TPS diets (n ¼ 4) starting from weaning until 27 weeks of age. The highest incidence of both preneoplastic and neoplastic lesions was found in mice maintained on the 0.4 and 0.1 ppm Se diets. Surprisingly, both Se deficiency (0 ppm Se) and high doses of Se (2.25 ppm Se and TPS) significantly inhibited all stages of neoplastic development, including foci, adenomas, and carcinomas, as compared to the 0.4 ppm Se group (Figure 2a ). In addition, the tumor multiplicity was also significantly reduced in these three groups of Hepatic dysplasia was evident in all livers from TGFa/c-Myc transgenic mice regardless of the diet. However, the degree of dysplasia was strikingly different between the five dietary groups. TGFa/c-Myc transgenic mice maintained on 0.1 and 0.4 ppm Se diets showed highly proliferative diffuse small cell dysplasia resulting in a marked disorganization of the lobular architecture ( Figure 3a ). In contrast, mice receiving 0 or 2.25 ppm Se displayed mainly large dysplastic cells undergoing a frequent apoptotic death (Figure 3b-d) . Furthermore, large areas of necrosis and inflammatory infiltrates within preneoplastic and neoplastic hepatic lesions were detected in TGFa/c-Myc mice fed the 2.25 ppm Se diet ( Figure 3d ). Transgenes probably caused or contributed to the observed lesions and infiltrates as inflammation and neoplasia were not evident in control (wild type) mice receiving 2.25 ppm Se (data not shown).
To better define the effect of Se treatment on tumor development, we next determined mitotic and apoptotic indices in TGFa/c-Myc livers (Figure 2c, d) . The highest rate of cell proliferation was found in mice receiving 0.4 ppm Se when compared with that in either 0 ppm, 2.25 ppm or TPS groups (P ¼ 0.001, 6.25E-05, 0.049, respectively) (Figure 3a) . In contrast, the rate of apoptosis was significantly higher in mice fed 2.25 ppm Se, 0 ppm Se, and TPS diets (P ¼ 4.6E-06, 3E-06, 0.0001 vs the 0.4 ppm Se group, respectively) (Figures 2d, 3b) . The resulting mitosis/apoptosis ratios were considerably reduced in the 2.25 ppm Se, 0 ppm Se and TPS dietary groups coincidently with decreased tumor growth. Of importance, the most frequent apoptotic cell death was found in association with extensive inflammatory infiltrates found in mice fed 2.25 ppm Se diet suggesting that high levels of Se might promote immune surveillance (Figure 3d ). Taken together, these data indicate that both low and high levels of dietary Se decrease the severity of dysplastic lesions and tumor formation in TGFa/c-Myc transgenic mice. In particular, high levels of Se might inhibit liver tumor development by inducing a proapoptotic state and favoring immune response against the tumor.
Gene expression changes in response to Se deficiency and high Se in TGFa/c-Myc mice
To gain further insights into the mechanism of suppressed hepatocarcinogenesis in TGFa/c-Myc mice maintained on the Se-deficient (0 ppm Se) and high Se (2.25 ppm. Se) diets, we compared gene expression profiles using Affymetrix mouse oligonucleotide chips representing B60% of mouse genes (Supplementary Figure S2) . The analysis was performed at the stage preceding major tumor formation (21 weeks on the diet) on two mice from each (0, 0.4 and 2.25 ppm Se) dietary groups (the full data set is at http://genomics.unl.edu/ CANCER). Changes in gene expression in response to dietary Se deficiency (0 ppm Se) or high levels of Se (2.25 ppm Se) were compared vs the 0.4 ppm Se group. Subsequently, genes affected in 0 and 2.25 ppm Se samples were compared against each other to identify unique and common alterations in gene expression between these two groups.
As expected, we found that several selenoprotein genes showed decreased mRNA levels in mice fed the 0 ppm Se diet (Table 1) , but these did not change when 0.4 and 2.25 ppm Se samples were compared. Additional unique responses of 0 and 2.25 ppm Se groups included genes involved in cell cycle, apoptosis, transcription, redox regulation, fatty acid metabolism, protein folding and immune/inflammatory response (Supplementary  Tables S1 and S2) .
Surprisingly, we also observed a very significant coregulation of genes in response to 0 and 2.25 ppm Se diets (Supplementary Figure S3 and Table S3 ). Among the genes with elevated expression in both 0 and 2.25 ppm Se groups, most prominent were genes responsible for detoxification and repair, as well as the proteins involved in redox regulation (Table 2) . In particular, a number of glutathione-S-transferases and cytochrome P450s manifested dramatically elevated gene expression.
These observations are consistent with the idea that repair/detoxification systems are upregulated during both Se deficiency and exposure to high levels of Se, thereby contributing to suppression of tumorigenesis observed in TGFa/c-Myc transgenic mice. Although a possible contribution of variable amounts of neoplastic tissue to some of the observed effects in gene expression cannot be excluded, we also observed increased expression of certain detoxification enzymes in other animal models subjected to Se diets (unpublished data).
To verify the microarray data, we assayed expression of two proteins, 3b hydroxysteroid dehydrogenase (3bHSD) and pancreatitis-associated protein (PAP) (Figure 1f) . Expression of 3bHSD and PAP mRNAs was strongly affected by both 0 and 2.25 ppm Se diets (relative to the 0.4 ppm Se diet) ( Table 2 and Supplementary Table S3 ), but they responded in an opposite manner to the Se diets. Consistent with these mRNA Mechanisms of cancer prevention by selenium in mice SV Novoselov et al changes, 3bHSD expression increased in response to both the 0 and 2.25 ppm Se diets, whereas expression of PAP decreased in both diets, relative to the 0.4 ppm Se diet (Figure 1f ).
Discussion
The goal of this study was to examine the cancer preventive effect of selenoproteins and low molecular weight Se compounds in the same animal model. The TGFa/c-Myc double transgenic mice, which exhibit a high penetrance of liver cancer, were chosen as a well characterized model relevant to human liver disease (Santoni-Rugiu et al., 1996; Factor et al., 1998; Hironaka et al., 2003) . In these mice, constitutive coexpression of c-Myc and TGFa in the liver generates an oxidative stress environment prior to tumor development and predisposes mice to a 100% incidence of HCC by 6-8 months of age (Calvisi et al., 2004) . Importantly, vitamin E, a potent free radical scavenging antioxidant, was able to protect liver tissue against oxidative stress and suppress hepatic tumor formation in TGFa/c-Myc mice (Factor et al., 2000) .
Admittedly, we initially anticipated that optimally increased levels of Se (0.4 ppm) would similarly normalize redox homeostasis by elevating expression of certain selenoproteins and hypothesized that it would result in suppression of the tumorigenesis process in the TGFa/cMyc mice. On the contrary, we found that selenoprotein deficiency significantly suppressed hepatic tumor forma- Fold change is shown for mice fed the 0 ppm Se diet relative to the 0.4 ppm Se diet and for mice fed the 2.25 ppm Se diet relative to the 0.4 ppm Se diet. TGFa/c-Myc mice (24 months old) were used, which were fed Se diets from weaning. Each dietary group had two independent samples and the average fold change in mRNA levels is shown Fold change is shown for mice fed the 0 ppm Se diet relative to the 0.4 ppm Se diet and for mice fed the 2.25 ppm Se diet relative to the 0.4 ppm Se diet. TGFa/c-Myc mice (24 months old) were used, which were fed Se diets from weaning. Each dietary group had two independent samples and the average fold change in mRNA levels is shown tion. To our knowledge, this is the first demonstration of a lower HCC incidence in response to Se deficiency. The increase in dietary Se levels from 0 to 0.4 ppm of Se resulted in elevated expression of various selenoproteins, as assessed by Affymetrix chips, enzyme assays, and immunoblot analyses. Antioxidant selenoproteins GPx1 and SelR were particularly responsive to Se supplementation. Sep15 and TR1 also responded, although the changes in expression were less pronounced. Expression of TR3 remained constant regardless of the Se diet. At low levels of dietary Se, selenoproteins account for the major part of Se in the body. Thus, there was a clear correlation between overall selenoprotein expression and increased tumorigenesis in the TGFa/c-Myc mice.
Although both tumor incidence and tumor multiplicity were similarly decreased in mice receiving high levels of Se in the diet, this decrease did not correlate with selenoprotein expression, as the 0.4 ppm Se already saturated selenoprotein expression. These data suggest that low molecular weight Se compounds are responsible for the chemopreventive effect of higher doses of dietary Se in the TGFa/c-Myc mice. Thus, both selenoprotein deficiency and high levels of Se compounds independently inhibited tumorigenesis in TGFa/ c-Myc mice. Such a correlated effect of Se deficiency and high levels of Se (as compared to optimal Se levels) has not been previously reported.
Moreover, both Se deficient and high Se diets resulted in decreases in cell proliferation and increases in apoptosis. A likely possibility is that high doses of Se (2.25 ppm Se and TPS) are cytotoxic, particularly for preneoplastic and cancer cells. It appears that decreased expression of selenoproteins observed in mice fed the 0 ppm Se diet was also cytotoxic as it promoted apoptosis and decreased the frequency of mitosis concomitantly with inhibition of tumorigenesis. In addition, we observed upregulation of mRNAs for repair and detoxification proteins, such as glutathione-S-transferases, cytochrome P450s, and glutaredoxin, under conditions of both Se deficiency (0 ppm Se) and high levels of Se (2.25 ppm Se). Although our study did not employ chemicals to induce tumorigenesis, it seems possible that the low levels of antioxidant selenoproteins may have increased the demand for detoxification of endogenous toxic compounds and for repair of damaged macromolecules. Thus, cytotoxicity may be a common feature associated with both Se deficiency and high levels of Se suggesting that detoxification and repair mechanisms may contribute to or be responsible for suppression of tumorigenesis in this animal model.
Our findings are consistent with the known inhibitory effect of antioxidant selenoproteins on apoptosis (Fu et al., 2001; Gouaze et al., 2002) . Previous studies reported elevated expression of detoxification and repair enzymes in Se-deficient mouse livers (Reiter and Wendel, 1984; Carlson et al., 2004) , as well as in cells treated with high levels of Se (El-Bayoumy and Sinha, 2004; Zhao et al., 2004) . In addition, Se deficiency had a protective effect against acetaminophen and aflatoxin injuries in rat livers, presumably due to stimulation of GSH synthesis and induction of expression of detoxification enzymes (Burk and Lane, 1983; Hill and Burk, 1984) .
Our data also agree with the recent report that Se deficiency abrogated peritoneal plasmacytomas in BALB/c mice, the experimental model of inflammation-dependent plasma cell transformation (Felix et al., 2004) . Thus, the role of Se and selenoproteins in cancer and the other findings reported in our study are likely not limited to strain, organ, and type of tumor that were examined.
When used in physiological levels, Se is often viewed as antioxidant that works in concert with vitamin E. However, vitamin E decreased tumorigenesis in TGFa/ c-Myc mice (Factor et al., 2000) , suggesting that at least in this mouse model, these compounds may have opposite effects. Besides, different selenoproteins may influence carcinogenesis in various ways (Gladyshev et al., 1998) . Whereas some, such as GPx1, are antioxidant proteins with well-defined functions, the contribution of other selenoproteins may be more complex. For example, TR1, the enzyme controlling the redox state of thioredoxin, is implicated in a myriad of cellular functions (Arner and Holmgren, 2000) . Thioredoxin serves as an antioxidant and antitumor protein by reducing thioredoxin peroxidase and controlling the redox state of tumor suppressor p53. However, it also reduces various transcription factors and provides electrons for deoxyribonucleotide biosynthesis. Thus, Se deficiency, by suppressing TR1 expression, may reduce the antioxidant and tumor suppressor capacity of the thioredoxin system as well as inhibit growth control functions. It is possible that in the TGFa/c-Myc model, growth inhibitory functions of Se deficiency prevail over antioxidant functions thereby inhibiting carcinogenesis.
Our data have important (although indirect) implications for the use of dietary Se in cancer prevention in humans. Optimal levels of dietary Se, which are slightly above those needed for maximal expression of selenoproteins, were thought to provide health benefits, particularly in reducing cancer incidence (Rayman, 2000; Hatfield, 2001; Burk, 2002) . However, our new findings suggest a possibility that elevated Se might also promote tumorigenesis in certain genetic backgrounds. Thus, whereas the overall effect of Se, when assessed in large population groups (Clark et al., 1996; Yu et al., 1997) , may be positive, there might be individuals, in which Se supplementation may promote tumor formation. Although our studies cannot be directly applied to humans (e.g. severe Se deficiency is unlikely to occur in humans unless there is a disruption in the pathway of Se insertion), they establish a precedent for a similar effect of Se deficiency and high levels of Se on cancer incidence in the same model system.
Given the promising results of previous clinical trials involving dietary Se (Clark et al., 1996 , Yu et al., 1997 , a number of new trials have been initiated, including the Se and Vitamin E Cancer Prevention Trial (SELECT) that involves 32 400 male subjects (Klein et al., 2000) .
Despite the extent of ongoing clinical trials, basic knowledge of the types of cancer that are prevented by Se and the mechanism of the chemopreventive effect is lacking. If the effect of Se on hepatocarcinogenesis that we observed in the TGFa/c-Myc mice can be seen in other mouse models or in subsets of the human population, it would mean that certain human cancers may be promoted by Se supplementation. Thus, rather than generally increasing the intake of Se, it may be important to identify segments of the human population that can benefit from Se supplementation as well as those in which Se supplementation can increase cancer incidence.
Materials and methods
Mice and diets
Double transgenic TGFa/c-Myc mice were generated as described (Santoni-Rugiu et al., 1996) . Five different diets (Harland TekLad, Madison, WI, USA) were used: 0 ppm Se (Se-deficient), 0.1 ppm Se, 0.4 ppm Se, 2.25 ppm Se, and 30 ppm TPS. The diets were based on the Torula yeast Sedeficient diet. Se was provided in the form of sodium selenite (except for the TPS diet).
Previous reports indicated that B0.1 ppm Se is a minimal amount of Se that is sufficient for maximal expression of GPx1. Since maximal expression of plasma GPx is achieved at B55 mg/day Se in humans (Burk, 2002) , the 0.1 ppm Se mouse diet may be viewed as approximately corresponding to the human Recommended Dietary Allowance for adults. By analogy, the 0.4 ppm Se diet would correspond to supplementation of the human diet with 200 mg Se/day, which is the common amount of Se used in clinical trials (Clark et al., 1996) . The rationale for the 2.25 ppm Se diet was based on the average amount of Se that was required for the chemopreventive effect of Se against chemically induced carcinogenesis in rodents (Ganther, 1999; Ip et al., 2002; Whanger, 2004) . Finally, TPS was recently introduced as a cancer preventive compound (Ip et al., 1998) . Even at very high (30 ppm) levels, TPS-derived Se was not accessible for insertion into selenoproteins, and thus, high levels of low molecular weight Se compounds were achieved under conditions of selenoprotein deficiency (Ip et al., 1998) . Se-deficient and high Se diets have been used in numerous previous studies involving rodents. These diets, as well as the TPS diet, provide excellent tools for the studies on the mechanisms of cancer prevention by Se in animal model systems. One limitation of these diets, however, is that the data can only partially be extrapolated to humans, as severe Se-deficient and Se-enriched conditions are unlikely to occur in humans.
Prior to the TGFa/c-Myc dietary study, we tested the Se diets using wild-type mice, which were housed in groups of three. After 2 months on the diets, the mice were killed and GPx1 activity was determined in each dietary group. The mice fed the 0 ppm Se diet had 3.6% of the GPx1 activity of mice on the 0.4 ppm Se diet. Likewise, the mice on the TPS diet had 4.5% of the GPx1 activity of the 0.4 ppm Se control. In addition, the diets were documented by analysing the amount of Se in the livers of wild-type mice fed 0.1 and 0 ppm Se diets. We found that the 0 ppm Se livers had 10 times lower total Se content than the 0.1 ppm Se livers. The TGFa/c-Myc mice were housed in groups of 2-5 and had free access to food and water. The dietary interventions started from weaning.
Histology and tumor sampling
The mice were killed at 27 weeks of age by CO 2 inhalation. The liver and body weights as well as the number and the size of all grossly visible tumors were recorded. Representative samples of liver taken from each lobe were fixed in 10% neutral formalin at 41C overnight or frozen in liquid nitrogen and stored at À801C. Paraffin sections (5 mm) were stained with hematoxylin-eosin, and hepatocellular lesions were graded as foci, adenomas and carcinomas as described (Calvisi et al., 2004) . The data are presented as mean7s.e. For statistical comparison the Student's t-test was used.
Mitotic and apoptotic indices
Mitotic and apoptotic indices were scored in TGFa/c-Myc livers from at least four mice per diet group. Mitotic index was determined by counting mitotic figures on H&E-stained slides. For the apoptotic index, sections were stained with the ApoTag peroxidase in situ apoptosis detection kit (Serologicals Corporation, Norcross, GA, USA), and positive cells were counted under a light microscope at a magnification Â 200. Apoptotic cells, single, and closely clustered apoptotic bodies were all scored as single events. Mitotic and apoptotic indices were represented as a percentage (mean7s.e.) of the total cells counted (at least 2000 cells per animal).
Metabolic labeling
To label selenoproteins in TGFa/c-Myc mice, animals were injected with freshly neutralized 75 Se[selenite] (Research Reactor Facility, University of Missouri, Columbia, MO, USA), and after 48 h, the mice were killed, tissues removed, and proteins extracted, electrophoresed, and transferred onto PVDF membranes. Resulting transblots were analysed with a PhosphorImager.
Enzyme assays
GPx1 and catalase activities were assayed using BIOXITECH GPx-340 and BIOXITECH Catalase-520 kits (OxisResearch, Portland, OR, USA), respectively, according to the manufacturer's protocol. The methionine-R-sulfoxide reductase activity of SelR was assayed as described previously (Kim and Gladyshev, 2004) . Liver homogenates from eight animals from each group (except the TPS dietary group that had four animals) were used and each sample was analysed in triplicate.
Selenoprotein expression analyses
TR1 (cytosolic enzyme) and TR3 (this mitochondrial enzyme is also called TnxRd2 and TrxR2) expression was assessed by immunoblot assays with antibodies specific for each isozyme, after the enzymes were enriched by binding to ADP-Sepharose as described previously (Moustafa et al., 2001) . Expression of SelR, GPx1, and Sep15 was analysed by immunoblot assays with antibodies specific for these proteins.
Gene expression analyses
Affymetrix GeneChip System (Affymetrix, Santa Clara, CA, USA) was used to carry out gene expression analyses. Total RNA was extracted from two 0 ppm Se, two 0.4 ppm Se, and two 2.25 ppm Se frozen mouse livers using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) and RNeasy columns (Qiagen, Valencia, CA, USA). Double-stranded cDNA synthesis and biotinylation was carried out as described in the Expression Analysis Technical Manual (Affymetrix). Mouse 15K arrays were hybridized and scanned using Affymetrix GeneChip Scanner 3000. To compare gene expression, the data generated from the 0 ppm Se samples were averaged and analysed against averaged 0.4 ppm Se data. Likewise, the 2.25 ppm Se data were averaged and analysed against the 0.4 ppm Se data. Expression of 3bHSD and PAP were assayed by immunoblot assays with antibodies specific for each protein (kindly provided by Dr Ian Mason and purchased from R&D Systems, Minneapolis, MN, USA, respectively).
Abbreviations
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